Search / 1 result found

from
to
  • Updated

BLUFFDALE, Utah, May 4, 2021 /PRNewswire/ -- Med7, LLC (www.Med7cbd.com) and HempCo, Inc. announce the completion of a human clinical study in patients with Type II Diabetes using Purzorb® technology, now trademarked as Hempzorb81TM. "This study will provide our customers and providers with evidence based products not seen to this point in the Industrial Hemp and CBD market place," said Matt Smith, CEO of Med7. This study was done with support from the National Institutes of Health (NIH) as part of their small business grant program.